TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02181582
Drug: Emapunil
Normalized name: Emapunil
DrugBank: Emapunil (DB12666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single peroral administration
Study: NCT04374981
Drug: Montelukast 10mg
Normalized name: montelukast 10 MG
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT03277729
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03035942
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
Study: NCT03035942
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
Study: NCT04036435
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT01329042
Drug: Potassium-sodium citrate
Normalized name: potassium-sodium citrate (obsolete)
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment
Study: NCT03602235
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan is an alkylating agent coupled to an amino acid
Study: NCT02423343
Drug: Galunisertib
Normalized name: Galunisertib
DrugBank: Galunisertib (DB11911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02423343
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT03035942
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
Study: NCT01844648
Drug: NH004 tropicamide
Normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
Study: NCT00650247
Drug: Sumatriptan Succinate Tablets 100 mg
Normalized name: Sumatriptan Succinate
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT00005869
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005869
Drug: rubitecan
Normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03407976
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
Study: NCT03407976
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg Q3 weeks IV
Study: NCT03403829
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine maintenance chemotherapy
Study: NCT03346681
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
Study: NCT01366235
Drug: chloroquine phosphate 1000 mg
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg, 1day
Study: NCT01018550
Drug: AMG 853
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 853 5 mg (BID)
Study: NCT01018550
Drug: AMG 853
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 853 200 mg (QD)
Study: NCT01018550
Drug: AMG 853
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 853 25 mg (BID)
Study: NCT01018550
Drug: AMG 853
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 853 100 mg (BID)
Study: NCT03673605
Drug: Rivaroxaban 15 mg
Normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
Study: NCT00882778
Drug: eptacog alfa (activated)
Normalized name: Eptacog alfa (activated)
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
Study: NCT03691311
Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Normalized name: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two injections on days 1 and 8 previous to surgery breast cancer excision
Study: NCT00404495
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 10 mg/m\^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
Study: NCT00404495
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 100-125 mg/m\^2 daily on days 1-5 in repeated 3 week cycles
Study: NCT02478866
Drug: BPI-9016M
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
Study: NCT03673605
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
Study: NCT02216656
Drug: KHK7580 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration
Study: NCT02216656
Drug: KHK7580 middle dose
Normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02216656
Drug: KHK7580 high dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02040857
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK 4/6 inhibitor
Study: NCT01515865
Drug: Midodrine HCl
Normalized name: midodrine HCl
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose at subject's current dose level
Study: NCT00068107
Drug: Replagal
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: enzyme replacement therapy
Study: NCT01033032
Drug: Amrubicin
Normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: dose-escalating portion with the starting dose of amrubicin at 90mg/m\^2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m\^2; DL3 - 110mg/m\^2; and DL4 - 120mg/m\^2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days
Study: NCT02609607
Drug: Bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal suppository
Study: NCT00191542
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00641537
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
Study: NCT00641537
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
Study: NCT00641537
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
Study: NCT01861041
Drug: Heavy Bupivacaine
Normalized name: bupivacaine hydrochloride Injectable Solution [Marcain Heavy]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7,5 mg intrathecal hyperbaric bupivacain,
Study: NCT01861041
Drug: Isobaric Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg intratecal isobaric bupivacain
Study: NCT00000170
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine
Study: NCT03884530
Drug: Ticagrelor (Brilique) 90
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug name Brilique 90 ml Drug form tablet
Study: NCT03884530
Drug: Aspirin 75mg
Normalized name: ASPIRIN 75MG CHEW TAB
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug name Aspirin 75 ml Drug form tablet
Study: NCT01132248
Drug: Mefloquine
Normalized name: Mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
Study: NCT01132248
Drug: S/P
Normalized name: Adenovirus/PNP
DrugBank: Adenovirus/PNP (DB17175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
Study: NCT00030667
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT03687333
Drug: ALGLUCOSIDASE ALFA (MYOZYME)
Normalized name: ALGLUCOSIDASE ALFA (MYOZYME) 50MG/VIL INJ
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion
Study: NCT03728426
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive intravenous or oral letermovir at a dose of 480mg/day.~Patients weighing 40 or more kilograms will receive a second, loading, dose 12 hours after the first dose of letermovir treatment.~For patients receiving concomitant cyclosporine treatment, the letermovir dose will be 240mg/day.
Study: NCT03961958
Drug: Propofol reduction
Normalized name: reductic acid
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduction of propofol target concentration
Study: NCT00177242
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04470544
Drug: Camostat Mesilate
Normalized name: Camostat mesilate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03592667
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg, one per day before breakfast during 12 weeks.
Study: NCT00876538
Drug: Olesoxime (TRO19622)
Normalized name: Olesoxime
DrugBank: Olesoxime (DB05185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of TRO19622 (330 mg) once day with the noon meal
Study: NCT04487067
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg IV infusion q3w
Study: NCT04487067
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg IV Q3W
Study: NCT06245681
Drug: gender affirming hormone therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio
Study: NCT01908829
Drug: mirabegron 25 mg
Normalized name: mirabegron 25 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
Study: NCT01908829
Drug: mirabegron 50 mg
Normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
Study: NCT01908829
Drug: solifenacin 5 mg
Normalized name: solifenacin 5 mg oral tablet
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
Study: NCT01908829
Drug: solifenacin 10 mg
Normalized name: solifenacin 10 mg oral tablet
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
Study: NCT01908829
Drug: mirabegron 25 mg matching placebo
Normalized name: mirabegron 25 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study: NCT01908829
Drug: mirabegron 50 mg matching placebo
Normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study: NCT01908829
Drug: solifenacin 5 mg matching placebo
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study: NCT01908829
Drug: solifenacin 10 mg matching placebo
Normalized name: solifenacin succinate 10 MG
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study: NCT03745729
Drug: allopurinol sustained-release capsules
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: allopurinol sustained-release capsules (0.25g), once a day, one pill at a time
Study: NCT02932774
Drug: Cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
Study: NCT02932774
Drug: Loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
Study: NCT01965405
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
Study: NCT00062881
Drug: Intrathecal Mafosfamide
Normalized name: Ifosfamide
DrugBank: Mafosfamide (DB12083)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01895270
Drug: Isradipine
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine extended release formulation
Study: NCT02320058
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02320058
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00541996
Drug: vabicaserin
Normalized name: Vabicaserin
DrugBank: Vabicaserin (DB12071)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03646526
Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
Study: NCT03646526
Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
Study: NCT00236509
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00668226
Drug: Lactic acid (Dermacid)
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00305708
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00305708
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00886743
Drug: oprelvekin
Normalized name: oprelvekin
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection, 50 mg/kg, once daily
Study: NCT00297128
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg/m2 week 1, 250mg/m2 week 2-4
Study: NCT00756236
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
Study: NCT00756236
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
Study: NCT00127998
Drug: chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04565717
Drug: ALN-HSD
Normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-HSD will be administered by subcutaneous (SC) injection.
Study: NCT03942094
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily
Study: NCT02646774
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection
Study: NCT00127998
Drug: sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00127998
Drug: amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00127998
Drug: amodiaquine+artesunate
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00127998
Drug: amodiaquine+sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02060487
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
Study: NCT02060487
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
Study: NCT02060487
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
Study: NCT00127998
Drug: sulfadoxine-pyrimethamine+artesunate
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00127998
Drug: mefloquine
Normalized name: Mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00653328
Drug: atrasentan hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 10 mg orally everyday continuously beginning on Day 1.
Study: NCT00531713
Drug: Triiodothyronine
Normalized name: Triiodothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3